The role of histone methyltransferases in therapeutic resistance of NSCLC.

IF 3.2 3区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Epigenetics Pub Date : 2025-12-01 Epub Date: 2025-07-23 DOI:10.1080/15592294.2025.2536786

Fuze Zhu, Xudong Yang, Yanlong Yang, Xinghe Tong, Jie Jia, Xingkun Gu, Yunping Zhao, Xiaobo Chen

{"title":"The role of histone methyltransferases in therapeutic resistance of NSCLC.","authors":"Fuze Zhu, Xudong Yang, Yanlong Yang, Xinghe Tong, Jie Jia, Xingkun Gu, Yunping Zhao, Xiaobo Chen","doi":"10.1080/15592294.2025.2536786","DOIUrl":null,"url":null,"abstract":"<p><p>Conventional treatments, including chemotherapy, immunotherapy, targeted therapy and radiotherapy, are effective clinical strategies for non-small cell lung cancer (NSCLC) patients, which can significantly improve life quality and prolong survival time. However, the application of drugs in NSCLC patients inevitably leads to therapeutic resistance. In recent years, many studies have shown that histone methyltransferases (HMTs), including both protein arginine methyltransferases (PRMTs) and lysine methyltransferases (KMTs), play pivotal roles in tumor initiation, progression, and treatment resistance. This review synthesizes current insights into histone methylation dynamics driving therapeutic resistance, with a focus on key HMTs and their mechanisms. Additionally, we discuss the molecular mechanisms underlying histone methylation-mediated therapeutic resistance and potential therapeutic strategies targeting histone methylation for overcoming therapeutic resistance in NSCLC.</p>","PeriodicalId":11767,"journal":{"name":"Epigenetics","volume":"20 1","pages":"2536786"},"PeriodicalIF":3.2000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296068/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epigenetics","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1080/15592294.2025.2536786","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Conventional treatments, including chemotherapy, immunotherapy, targeted therapy and radiotherapy, are effective clinical strategies for non-small cell lung cancer (NSCLC) patients, which can significantly improve life quality and prolong survival time. However, the application of drugs in NSCLC patients inevitably leads to therapeutic resistance. In recent years, many studies have shown that histone methyltransferases (HMTs), including both protein arginine methyltransferases (PRMTs) and lysine methyltransferases (KMTs), play pivotal roles in tumor initiation, progression, and treatment resistance. This review synthesizes current insights into histone methylation dynamics driving therapeutic resistance, with a focus on key HMTs and their mechanisms. Additionally, we discuss the molecular mechanisms underlying histone methylation-mediated therapeutic resistance and potential therapeutic strategies targeting histone methylation for overcoming therapeutic resistance in NSCLC.

Abstract Image

查看原文本刊更多论文

组蛋白甲基转移酶在非小细胞肺癌耐药中的作用。

化疗、免疫治疗、靶向治疗、放疗等常规治疗方法是治疗非小细胞肺癌（NSCLC）患者的有效临床策略，可显著提高患者的生活质量，延长生存期。然而，药物在NSCLC患者中的应用不可避免地导致了治疗耐药性。近年来，许多研究表明，包括蛋白精氨酸甲基转移酶（PRMTs）和赖氨酸甲基转移酶（KMTs）在内的组蛋白甲基转移酶（HMTs）在肿瘤的发生、发展和耐药过程中起着关键作用。这篇综述综合了目前对组蛋白甲基化动力学驱动治疗耐药的见解，重点是关键的hmt及其机制。此外，我们还讨论了组蛋白甲基化介导的治疗耐药的分子机制，以及针对组蛋白甲基化克服非小细胞肺癌治疗耐药的潜在治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Epigenetics 生物-生化与分子生物学

CiteScore

6.80

自引率

2.70%

发文量

审稿时长

3-8 weeks

期刊介绍： Epigenetics publishes peer-reviewed original research and review articles that provide an unprecedented forum where epigenetic mechanisms and their role in diverse biological processes can be revealed, shared, and discussed. Epigenetics research studies heritable changes in gene expression caused by mechanisms others than the modification of the DNA sequence. Epigenetics therefore plays critical roles in a variety of biological systems, diseases, and disciplines. Topics of interest include (but are not limited to): DNA methylation Nucleosome positioning and modification Gene silencing Imprinting Nuclear reprogramming Chromatin remodeling Non-coding RNA Non-histone chromosomal elements Dosage compensation Nuclear organization Epigenetic therapy and diagnostics Nutrition and environmental epigenetics Cancer epigenetics Neuroepigenetics